,src,lang,text
0,"











Laba Kalbe Farma Tembus Rp 1,92 Triliun di Kuartal III 2019
03 Nov 2019, 07:39 by Bisnis.com, Dewi Rina Cahyani
TEMPO.CO, Jakarta - Emiten farmasi, PT Kalbe Farma Tbk. berhasil membukukan pertumbuhan kinerja positif selama periode 9 bulan pertama tahun ini, didorong strategi penaikan harga jual produk.
Berdasarkan laporan keuangan per 30 September 2019, produsen Extra Joss itu membukukan penjualan bersih sebesar Rp16,83 triliun, tumbuh 7,33% secara tahunan.
Bernadus Karmin Winata, Direktur Keuangan dan Sekretaris Perusahaan Kalbe, mengatakan di tengah kondisi yang menantang, perseroan mampu membukukan pertumbuhan positif dengan menerapkan kenaikan harga sebesar 3-5 persen secara selektif pada produk nutrisi.
Penjualan ditopang penjualan segmen distribusi dan logistik yang tumbuh 13,81 persen menjadi Rp 5,31 triliun, diikuti segmen nutrisi yang tumbuh 4,58 persen menjadi Rp 4,84 triliun.
Sementara itu, penjualan segmen obat resep tumbuh 6,57 persen menjadi Rp 3,92 triliun, serta segmen produk kesehatan tumbuh 1,90 persen menjadi Rp 2,76 triliun.
Di pasar domestik, penjualan Kalbe tumbuh 8,01 persen menjadi Rp 15,98 triliun. Sebaliknya penjualan di pasar ekspor turun 4,10 persen menjadi Rp 845,52 miliar.
Kalbe tetap optimistis terhadap perbaikan kondisi ekonomi Indonesia dan kinerja perseroan. Di tengah kondisi yang menantang, pihaknya melanjutkan strategi untuk mendorong inovasi sebagai penggerak pertumbuhan di masa mendatang.
""Kami juga berupaya mengambil langkah-langkah perbaikan seperti pengendalian biaya dan peningkatan kualitas,"" katanya dalam keterbukaan informasi.
Emiten bersandi saham KLBF itu, mencatat kenaikan beban pokok penjualan 10,61 persen, beban penjualan naik 0,33 persen serta beban penelitian dan pengembangan naik 10,24 persen. Beban bunga dan keuangan juga naik 24,30 persen secara tahunan.
Perusahaan mengantongi laba bersih senilai Rp 1,92 triliun per kuartal III/2019, tumbuh 6,15 persen dibandingkan periode yang sama tahun lalu sebesar Rp 1,80 triliun.
Bernadus menyebutkan margin laba bersih relatif stabil sebesar 11,4 persen. Adanya pertumbuhan laba bersih terutama disebabkan oleh meningkatnya penjualan dan efisiensi dalam mengelola biaya operasional.
""Dengan mempertimbangkan situasi rupiah yang cukup stabil serta kondisi kompetisi di pasar, perseroan mempertahankan target pertumbuhan penjualan bersih sebesar 6%-8%. Pertumbuhan laba bersih juga diproyeksi pada kisaran yang sama,"" ujarnya.
Target margin laba sebelum pajak ditetapkan stabil pada tingkat 14,5-15,5 persen. Perseroan juga menyiapkan anggaran belanja modal sebesar Rp 1,5 triliun - Rp 2 triliun yang akan digunakan untuk perluasan kapasitas produksi dan distribusi, transformasi digital dan produk biologi. Rasio pembagian dividen pada kisaran 45-55 persen dengan memperthatikan ketersediaan dana dan kebutuhan pendanaan internal.
Kalbe Farma memiliki total aset senilai Rp19,60 triliun per 30 September 2019, naik 7,98 persen dari total aset per 31 Desember 2018 sebesar Rp 18,15 triliun. Adapun jumlah liabilitas sebesar Rp 3,46 triliun dan ekuitas Rp 16,14 triliun.


",id,"











Kalbe Farma's Profit Reaches Rp 1.92 Trillion in the Third Quarter of 2019
03 Nov 2019, 07:39 by Bisnis.com, Dewi Rina Cahyani
TEMPO.CO, Jakarta - Pharmaceutical issuer, PT Kalbe Farma Tbk. managed to record positive performance growth during the first 9 months of this year, driven by a product price increase strategy.
Based on financial statements as of September 30, 2019, the Extra Joss producer posted a net sales of Rp16.83 trillion, growing 7.33% on an annual basis.
Bernadus Karmin Winata, Kalbe's Finance Director and Corporate Secretary, said in the midst of challenging conditions, the company was able to record positive growth by implementing price increases of 3-5 percent selectively in nutritional products.
Sales were supported by sales and distribution segments, which grew 13.81 percent to Rp 5.31 trillion, followed by the nutritional segment which grew 4.58 percent to Rp 4.84 trillion.
Meanwhile, sales of the prescription drug segment grew 6.57 percent to Rp 3.92 trillion, and the health product segment grew 1.90 percent to Rp 2.76 trillion.
In the domestic market, Kalbe's sales grew 8.01 percent to Rp 15.98 trillion. On the other hand, sales in the export market dropped 4.10 percent to Rp 845.52 billion.
Kalbe remains optimistic about improving Indonesia's economic conditions and the company's performance. In the midst of challenging conditions, it continues its strategy to encourage innovation as a driver of growth in the future.
""We are also trying to take corrective measures such as cost control and quality improvement,"" he said in a disclosure.
The issuer coded KLBF shares recorded an increase in cost of goods sold of 10.61 percent, selling expenses rose 0.33 percent and research and development expenses rose 10.24 percent. Interest and financial expenses also rose 24.30 percent annually.
The company pocketed a net profit of Rp 1.92 trillion per quarter III / 2019, growing 6.15 percent compared to the same period last year of Rp 1.80 trillion.
Bernadus said that the net profit margin was relatively stable at 11.4 percent. The growth in net profit was mainly due to increased sales and efficiency in managing operating costs.
""Taking into account the rupiah's relatively stable situation and competitive conditions in the market, the company maintains a net sales growth target of 6% -8%. Net profit growth is also projected in the same range,"" he said.
The profit margin target before tax is set to be stable at 14.5-15.5 percent. The company is also preparing a capital expenditure budget of Rp 1.5 trillion - Rp 2 trillion which will be used to expand production and distribution capacity, digital transformation and biological products. The dividend distribution ratio is in the range of 45-55 percent with regard to the availability of funds and internal funding needs.
Kalbe Farma has total assets of Rp19.60 trillion as of 30 September 2019, up 7.98 percent from total assets as of 31 December 2018 of Rp 18.15 trillion. The total liabilities were IDR 3.46 trillion and equity IDR 16.14 trillion.


"
